Analysis for CTAS

📈 Growth & Financial Trajectory

Over the 8 quarters, CTAS demonstrates a steady revenue base, expanding from about $2.471B to $2.841B (+~15%). Net income grows from about $414M to $502M (+~21%), despite quarterly volatility. Gross margin remains robust, around 50%–56%, with a peak in late 2025 and a normalization near the latest quarter, and operating margin around the high teens to low twenties. These dynamics underpin a solid earnings trajectory.

💰 Margins & Cash Flow

Gross profit remains strong (latest quarter ~$1.45B on $2.84B revenue). Operating margin stays around the low-to-mid 20s; evidence of operating leverage. Cash flow from operations is healthy, with latest quarter net cash from operating activities near $621M, while investing and financing activity offset cash flow, yielding a small quarterly net cash outflow of about $17M. Free cash flow remains substantial on an annual basis given stable capex.

🛡️ Balance Sheet & Liquidity

Assets run around $9.8–10.3B and liabilities about $5.0–5.6B, with equity roughly $4.3–4.8B. Current ratio typically near 1.7–2.0, indicating solid liquidity. Long-term debt around $2.0–2.6B provides modest leverage; coverage through operating cash flow appears comfortable.

⚠️ Key Drivers & Risks

• Drivers: Recurring service model, strong scale in diversified customer segments (industrial/healthcare) driving stable cash flow; potential efficiency-driven demand.
• Risks: Economic downturns could pressure client budgets; margin compression from input costs or competitive pricing pressure.